Gene · 10481
Papers1,917
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,917
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A single cell transcriptional profile of benign prostatic hyperplasia. | Sci Rep | 2026 | 41832222 | PubTator, text mining | PubMed |
| Precision diagnosis and therapy for pediatric central nervous system tumors: consensus from the Brazilian Society of Pediatric Oncology (SOBOPE). | Lancet Reg Health Am | 2026 | 41808847 | PubTator, text mining | PubMed |
| Prostate‑specific membrane antigen: Molecular functions and emerging roles as a therapeutic target (Review). | Mol Med Rep | 2026 | 41789574 | PubTator, text mining | PubMed |
| Polygenic risk and germline genetics for prostate cancer in Asians: Where do we stand? | Investig Clin Urol | 2026 | 41775441 | PubTator, text mining | PubMed |
| From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis. | Transl Oncol | 2026 | 41762538 | PubTator, text mining | PubMed |
| Genomic Landscape and Therapeutic Implications of Metaplastic Breast Carcinoma: Insights from a Nationwide Database Including Diagnostic Mimickers. | Pharmaceuticals (Basel) | 2026 | 41754851 | PubTator, text mining | PubMed |
| PARP Inhibitors Combined with Abiraterone Overcome Resistance in Metastatic Castration-Resistant Prostate Cancer Independently of Androgen Receptor. | Cancers (Basel) | 2026 | 41749814 | PubTator, text mining | PubMed |
| Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer. | J Natl Cancer Cent | 2026 | 41738039 | PubTator, text mining | PubMed |
| Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer. | J Natl Cancer Cent | 2026 | 41738035 | PubTator, text mining | PubMed |
| Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance. | J Natl Cancer Cent | 2026 | 41738032 | PubTator, text mining | PubMed |
| Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer. | J Natl Cancer Cent | 2026 | 41738031 | PubTator, text mining | PubMed |
| Obesity-linked genes may promote prostate cancer among Asian and Hispanic immigrants to North America. | Front Public Health | 2026 | 41737617 | PubTator, text mining | PubMed |
| The role of epigenetic modifications in hematological cancers. | Front Oncol | 2026 | 41727658 | PubTator, text mining | PubMed |
| SOGUG Multidisciplinary Expert Panel Consensus on Updated Diagnosis and Characterization of Prostate Cancer Patients. | Curr Oncol | 2026 | 41590381 | PubTator, text mining | PubMed |
| Role of hsa-miR-122-5p in chronic thromboembolic pulmonary hypertension and chronic thromboembolic disease: Targeting PIK3CG in the PI3K/Akt signaling pathway. | Medicine (Baltimore) | 2026 | 41560055 | PubTator, text mining | PubMed |
| Regulation of androgen receptor expression by enhancer elements in prostate cancer. | Exp Mol Med | 2026 | 41545686 | PubTator, text mining | PubMed |
| Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review). | Int J Oncol | 2026 | 41347816 | PubTator, text mining | PubMed |
| Utility of HoxB13 in differential diagnosis of female genital tract lesions with putative prostatic differentiation. | Virchows Arch | 2026 | 41335140 | PubTator, text mining | PubMed |
| The Role of Genetic Testing in Localized Prostate Cancer. | Urol Clin North Am | 2026 | 41266002 | PubTator, text mining | PubMed |
| Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry. | Eur Urol | 2026 | 41219045 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10481/papers?page=2